Texas Medical Center Innovation Institute kicks off third accelerator program

More than 11 medical device startups will head to Texas for the third installment of TMCx, an accelerator program that helps startups partner with industry experts that can help turn entrepreneur’s device concepts into reality.

The Texas Medical Center Innovation Institute is a 15-week program in Houston that lets startups collaborate with top industry and business experts, physicians and scientists, and stakeholders.

Startups attending the program this year include Bloom Labs, a New York-based company that creates credit-card sized rescue inhalers, San Francisco-based Blumio, which creates a sensor to measure blood pressure continuously, and WeaRobot, a Mexico-based company that has developed a concept for an active exoskeleton for seniors and the physically impaired. For a complete list of startups attending the program, click here.

"Very few accelerators have a robust program devoted to medical device startups, so we are filling a huge gap in the life sciences ecosystem," said Erik Halvorsen, PhD, director of the TMC Innovation Institute, in a statement. "Now we are the only accelerator in the country that runs alternating curriculum tracks on med devices and digital health, which will bolster our efforts to attract top talent in health care innovation."

The startups will be guided through areas like intellectual property, product development, regulatory strategies, health policy, marketing, fundraising, contract negotiations and communications. The program runs through November, at which point the companies will make a final pitch to advisors, hospital stakeholders and investors.

Applications for next year’s program will begin being accepted Aug. 17.

 

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.